Transgene presented updated results from its Ph II study in HPV-16 positive anogenital cancers at ASCO 2023.

Following this presentation, Invest Securities confirms its Buy recommendation on the stock and its price target of 5.4 E.

'The data highlight a strong correlation between observed immunological responses and clinical responses. Indeed, the strongest clinical responses were obtained in patients who also showed the strongest immune responses against HPV antigens E6 and E7', says the analyst.

At this stage, 58% of patients who received the TG4001/avelumab combo showed an increase in immune responses against HPV, compared with 9% of patients who received avelumab alone. In addition, 11 of the 13 patients who developed an immune response showed stabilization or even regression, underlining the correlation between biological and clinical responses' adds Invest Securities.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.